scholarly journals Pathogenic Mechanism of Dry Eye–Induced Chronic Ocular Pain and a Mechanism-Based Therapeutic Approach

2022 ◽  
Vol 63 (1) ◽  
pp. 7
Author(s):  
Yuto Tei ◽  
Yoshinori Mikami ◽  
Masanori Ito ◽  
Taichiro Tomida ◽  
Daisuke Ohshima ◽  
...  
Keyword(s):  
Dry Eye ◽  
Therapeutic Approach ◽  
Pathogenic Mechanism ◽  
Ocular Pain

scholarly journals Topical TRPM8 Agonist for Relieving Neuropathic Ocular Pain in Patients with Dry Eye: A Pilot Study

2021 ◽  
Vol 10 (2) ◽  
pp. 250
Author(s):  
Hyeon Jeong Yoon ◽  
Jonghwa Kim ◽  
Jee Myung Yang ◽  
Edward T. Wei ◽  
Seong Jin Kim ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Pilot Study ◽  
Pain Intensity ◽  
Dry Eye ◽  
Associated Factors ◽  
Treatment Result ◽  
Ocular Pain ◽  
Eye Pain ◽  
Validated Questionnaire

Background: Activation of TRPM8, a cold-sensing receptor located on the cornea and eyelid, has the potential to relieve the neuropathic ocular pain (NOP) in dry eye (DE) by inhibiting other aberrant nociceptive inputs. We aimed to investigate the effect of a topical TRPM8 agonist, cryosim-3 (C3), on relieving DE-associated NOP. Methods: We conducted a prospective pilot study of 15 patients with DE-associated NOP. These patients applied topical C3 to their eyelid, 4 times/day for 1 month. The patients underwent clinical examinations. They also completed the Ocular Pain Assessment Survey (OPAS), which is a validated questionnaire for NOP, at baseline, 1 week, and 1 month after treatment. Result: At 1 week, the OPAS scores of eye pain intensity, quality of life (driving/watching TV, general activity, sleep, and enjoying life/relations with other people), and associated factors (burning sensation, light sensitivity, and tearing) improved. The total OPAS scores of eye pain intensity, quality of life, and associated factors remained improved at 1 month. The Schirmer test scores also improved at 1 month. Conclusion: TRPM8 agonist (C3) could be a novel agent for treating patients with DE-associated NOP who are unresponsive to conventional treatments.

scholarly journals Neuropathic-Like Ocular Pain and Nonocular Comorbidities Correlate With Dry Eye Symptoms

2018 ◽  
Vol 44 ◽  
pp. S307-S313 ◽  
Author(s):  
Victoria S. Chang ◽  
Terri P. Rose ◽  
Carol L. Karp ◽  
Roy C. Levitt ◽  
Constantine Sarantopoulos ◽  
...  
Keyword(s):  
Dry Eye ◽  
Ocular Pain ◽  
Eye Symptoms ◽  
Dry Eye Symptoms

scholarly journals Characteristics of Ocular Pain Complaints in Patients With Idiopathic Dry Eye Symptoms

2017 ◽  
Vol 43 (3) ◽  
pp. 192-198 ◽  
Author(s):  
Jerry P. Kalangara ◽  
Anat Galor ◽  
Roy C. Levitt ◽  
Derek B. Covington ◽  
Katherine T. McManus ◽  
...  
Keyword(s):  
Dry Eye ◽  
Ocular Pain ◽  
Eye Symptoms ◽  
Dry Eye Symptoms

Ocular pain response to treatment in dry eye patients

2020 ◽  
Vol 18 (2) ◽  
pp. 305-311 ◽  
Author(s):  
Andrew N. Siedlecki ◽  
Scott D. Smith ◽  
Adam R. Siedlecki ◽  
Salim M. Hayek ◽  
Rony R. Sayegh
Keyword(s):  
Dry Eye ◽  
Response To Treatment ◽  
Pain Response ◽  
Ocular Pain

Bowman Break and Subbasal Nerve Plexus Changes in a Patient With Dry Eye Presenting With Chronic Ocular Pain and Vitamin D Deficiency

Cornea ◽  
2016 ◽  
Vol 35 (5) ◽  
pp. 688-691 ◽  
Author(s):  
Rohit Shetty ◽  
Kalyani Deshpande ◽  
Rashmi Deshmukh ◽  
Chaitra Jayadev ◽  
Rushad Shroff
Keyword(s):  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Dry Eye ◽  
Nerve Plexus ◽  
Ocular Pain ◽  
Subbasal Nerve Plexus

scholarly journals Neuropathic Ocular Pain due to Dry Eye Is Associated With Multiple Comorbid Chronic Pain Syndromes

2016 ◽  
Vol 17 (3) ◽  
pp. 310-318 ◽  
Author(s):  
Anat Galor ◽  
Derek Covington ◽  
Alexandra E. Levitt ◽  
Katherine T. McManus ◽  
Benjamin Seiden ◽  
...  
Keyword(s):  
Chronic Pain ◽  
Dry Eye ◽  
Ocular Pain ◽  
Pain Syndromes ◽  
Chronic Pain Syndromes

scholarly journals Clinical Characteristics of Dry Eye with Ocular Neuropathic Pain Features: Comparison According to the Types of Sensitization Based on the Ocular Pain Assessment Survey

2020 ◽  
Author(s):  
Jonghwa Kim ◽  
Hyeon Jeong Yoon ◽  
In Cheon You ◽  
Byung Yi Ko ◽  
Kyung Chul Yoon
Keyword(s):  
Neuropathic Pain ◽  
Dry Eye ◽  
Ocular Surface ◽  
Clinical Characteristics ◽  
Tear Film ◽  
Meibomian Gland ◽  
Burning Sensation ◽  
Ocular Pain ◽  
Central Group ◽  
Assessment Survey

Abstract Background: To compare the clinical characteristics of dry eye patients with ocular neuropathic pain features according to the types of sensitization based on the Ocular Pain Assessment Survey (OPAS).Methods: Cross-sectional study of 33 patients with dry eye and ocular neuropathic pain features. All patients had a comprehensive ophthalmic assessment including detailed history, the intensity and duration of ocular pain, the tear film, ocular surface, and Meibomian gland examination, and OPAS. Patients with <50% improvement in pain intensity after proparacaine challenge test were assigned to the central-dominant sensitization group (central group) and those with ≥50% improvement were assigned to the peripheral-dominant sensitization group (peripheral group). All variables were compared between the two groups.Results: No significant differences were observed in age, sex, underlying diseases, history of ocular surgery, duration of ocular pain, tear film, ocular surface and Meibomian gland parameters (all p>0.05). Ocular pain and non-ocular pain severity and the percentage of time spent thinking about non-ocular pain were significantly higher in the central group than in the peripheral group (all p<0.05). Central group complained more commonly of a burning sensation than did the peripheral group (p=0.01).Conclusions: Patients with central-dominant sensitization may experience more intense ocular and non-ocular pain than the others and burning sensation may be a key symptom in those patients.

scholarly journals Treatment Response to Gabapentin in Neuropathic Ocular Pain Associated with Dry Eye

2020 ◽  
Vol 9 (11) ◽  
pp. 3765
Author(s):  
Hyeon-Jeong Yoon ◽  
Jonghwa Kim ◽  
Kyung Chul Yoon
Keyword(s):  
Medical History ◽  
Treatment Response ◽  
Dry Eye ◽  
Topical Treatment ◽  
Ocular Pain ◽  
Group 3 ◽  
Chemical Stimuli ◽  
Group 2 ◽  
Response Group ◽  
Group 1

Purpose: To investigate the response to gabapentin treatment in patients with dry eye (DE) accompanied by features of neuropathic ocular pain (NOP), and to analyze the differences between clinical manifestations of the groups according to treatment response. Methods: We retrospectively reviewed the records of 35 patients with DE accompanied by NOP features and obtained information on their medical history and previous ocular history. The patients underwent clinical examinations of the tear film, ocular surface, and meibomian gland and completed the Ocular Pain Assessment Survey (OPAS). One month after treatment with topical eye drops, add-on of gabapentin treatment was determined according to the Wong–Baker FACES Pain Rating Scale (WBFPS). A reduction of 2 points or more on the WBFPS was considered a positive treatment response. Enrolled patients were divided into three groups according to the treatment response: topical treatment response group (group 1, n = 11); gabapentin response group (group 2, n = 13); and gabapentin non-response group (group 3, n = 11). The medical history, clinical parameters, and OPAS scores were compared between groups. Results: The incidence of systemic comorbidities was higher in group 2 than in other groups. The corneal staining scores were lower in groups 2 and 3 than in group 1. Among the treatment response groups, group 2 showed improvements in OPAS scores of ocular pain severity, pain other than eyes, and quality of life, while group 1 showed improved OPAS scores of ocular pain severity and ocular associated factors. Group 2 exhibited lower scores of pains aggravated by mechanical and chemical stimuli than group 3. Conclusions: Gabapentin could be effective in patients who have systemic comorbidity and less pain evoked by mechanical and chemical stimuli for the treatment of DE patients with NOP, which is refractory to topical treatment.

Sign in / Sign up

Export Citation Format

Share Document